Guide
Is BPC-157 FDA-approved?
The short answer is no for consumer longevity or injury claims; verify any product-specific claim against official FDA records.
Evidence:Regulatory watchRisk:High riskStatus:Not approved
Longevity guides and explainers
Plain-English guides for the claims people ask about, with evidence and approval context available when you want it.
More filters
24 guides
RSS
Guide
Does BPC-157 heal injuries in humans?
BPC-157 has animal and mechanism-heavy discussion, but that is not the same as strong human injury evidence.
Evidence:Mostly lab/animalRisk:High riskStatus:Not approved
Guide
What is TB-500 and how is it different from thymosin beta-4?
TB-500 is usually marketed as a peptide fragment related to thymosin beta-4, but naming can blur important evidence and quality questions.
Evidence:Early theoryRisk:High riskStatus:Not approved
Guide
Are compounded peptides FDA-approved?
Compounding can be lawful in some circumstances, but compounded drugs themselves are not FDA-approved products.
Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved
Guide
What the FDA peptide review could change in 2026.
A regulatory review can affect what compounders, clinics and consumers can claim, but it does not create human efficacy evidence by itself.
Evidence:Regulatory watchRisk:Moderate riskStatus:Status unclear
Guide
Research peptides: why purity, identity and sterility matter.
Before benefit claims, readers should ask whether the substance is what the label says and whether it is appropriate for human use.
Evidence:Commercial claimRisk:High riskStatus:Not approved
Guide
Does rapamycin slow aging in humans?
Rapamycin is one of the most discussed geroscience drugs, but human longevity evidence remains incomplete.
Evidence:Human trial evidenceRisk:High riskStatus:Off-label
Guide
What did the PEARL rapamycin trial actually show?
PEARL is important because it asks human questions, but readers should distinguish trial signals from sweeping longevity claims.
Evidence:Human trial evidenceRisk:High riskStatus:Off-label
Guide
Metformin for longevity: what TAME is trying to answer.
TAME is designed around whether one approved diabetes drug can affect multiple aging-related outcomes, but it is not a completed answer.
Evidence:Trial registeredRisk:Moderate riskStatus:Approved for another use
Guide
What does off-label mean in longevity medicine?
Off-label use is common in medicine, but it should not be confused with approval for anti-aging claims.
Evidence:Regulatory watchRisk:Moderate riskStatus:Off-label
Guide
NMN vs NR: what is the difference?
Both NMN and NR are NAD-related precursors, but chemistry, regulation and human evidence need to be kept separate.
Evidence:Human trial evidenceRisk:Moderate riskStatus:Supplement status
Guide
Do NAD supplements slow aging?
NAD biology is real, but the leap from NAD markers to human aging outcomes is larger than most ads admit.
Evidence:Human trial evidenceRisk:Moderate riskStatus:Supplement status
Guide
NAD IV drips: evidence, cost and unanswered questions.
IV NAD clinics sell a high-touch experience, but route of delivery does not solve the outcome-evidence problem.
Evidence:Commercial claimRisk:Moderate riskStatus:Status unclear
Guide
The longevity stack problem: why combinations are hard to interpret.
When multiple interventions change at once, impressive stories become hard to assign to any one ingredient.
Evidence:Evidence unclearRisk:Moderate riskStatus:Status unclear
Guide
Is age-reversal gene therapy real?
Gene therapy is real medicine in specific diseases; consumer age-reversal gene therapy is a much more speculative claim.
Evidence:Early theoryRisk:High riskStatus:Experimental
Guide
What is partial epigenetic reprogramming?
Partial reprogramming tries to reset aspects of cell state without erasing identity, but it remains frontier biology.
Evidence:Mostly lab/animalRisk:ExperimentalStatus:Experimental
Guide
What are OSK factors?
OSK refers to three reprogramming factors often discussed in cellular rejuvenation research.
Evidence:Early theoryRisk:ExperimentalStatus:Experimental
Guide
Approved gene therapy vs anti-aging gene therapy.
Approved gene therapies are specific products for specific diseases; anti-aging gene therapy claims need separate evidence and regulatory scrutiny.
Evidence:Regulatory watchRisk:ExperimentalStatus:Experimental
Guide
What is biological age?
Biological age is an attempt to estimate health or aging state, not a second birth certificate.
Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear
Guide
Are epigenetic clocks useful for individuals?
Epigenetic clocks can be powerful research tools, but personal interpretation is still a high-noise exercise.
Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear
Guide
The longevity biomarker map: VO2 max, ApoB, CGM, DEXA and HRV.
Some biomarkers are clinically actionable, some are performance markers and some are exploratory signals.
Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear
Guide
What are senescent cells?
Senescent cells are part of aging biology, but they are not simply bad cells to eliminate everywhere.
Evidence:Early theoryRisk:Moderate riskStatus:Status unclear
Guide
What are senolytics?
Senolytics are interventions intended to remove certain senescent cells, but most longevity claims remain early.
Evidence:Mostly lab/animalRisk:High riskStatus:Experimental
Guide
What actually works in longevity before experimental interventions?
The strongest foundation is not exotic: fitness, blood pressure, lipids, sleep, smoking avoidance, nutrition and preventive care.
Evidence:Human trial evidenceRisk:Lower riskStatus:Status unclear